BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Astralis, Ltd. (ASTR) Reports Second Quarter 2006 Results


8/22/2006 10:28:29 AM

FAIRFIELD, N.J., Aug. 21 /PRNewswire-FirstCall/ -- Astralis Ltd. (OTC Bulletin Board: ASTR - News) today announced its results for the second quarter 2006. For the three months ended June 30, 2006, the Company recorded a net loss of $403,769 to common stockholders. The Company, which is a development stage entity, had no revenue during this period. Total shareholders' equity as of June 30, 2006, was ($28,084) and the Company had a cash balance totaling $55,637 as of June 30, 2006. Research and development expenses for the second quarter 2006 amounted to $125,723.

As of the date of this press release, the Company's liabilities exceed its cash. If the Company does not acquire additional cash within days, it will be forced to cease operations.

ASTRALIS LTD (A DEVELOPMENT STAGE ENTITY) SELECTED STATEMENT OF OPERATION INFORMATION

Three Months March 31, 2006 - June 30, 2006 Revenues $-- Total Operating Expenses $405,217 Loss of Operations $(405,217) Investment Income $1,448 Net Loss Before Income Tax Benefit $(403,769) Income Tax Benefit $-- Net Loss to Common Stockholders $(403,769) Basic and diluted loss per common share $(0.00)

This press release may contain forward-looking statements regarding Astralis Ltd. Actual results may differ materially from those described in the press release as a result of a number of factors, including but not limited to the following: There can be no assurance that Psoraxine® will be successfully developed or manufactured, or that final results of human clinical trials will result in the regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of this product will be achieved. Astralis will continue its research and development effort to the extent that we do not experience any cash shortfalls, adverse developments in our drug development or competitive or other impediments that an early stage company in our industry may face. Astralis, Ltd. undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.

Source: Astralis Ltd.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES